头孢他啶-阿维巴坦对急性呼吸窘迫综合征合并铜绿假单胞菌呼吸道感染患者的治疗效果

Effect of ceftazidime-avibactam in acute respiratory distress syndrome patients with Pseudomonas aeruginosa respiratory infection

目的 探讨头孢他啶-阿维巴坦(CAZ-AVI)对急性呼吸窘迫综合征(ARDS)合并铜绿假单胞菌呼吸道感染患者的治疗效果。方法 60例急性呼吸窘迫综合征合并铜绿假单胞菌呼吸道感染患者,采用随机数表法分为对照组和实验组,每组30例。对照组接受基础治疗,实验组在对照组的基础上予以头孢他啶-阿维巴坦治疗。比较两组临床疗效、细菌清除情况以及治疗前后的白细胞介素(IL)-6、IL-8水平。结果 实验组治疗总有效率93.33%、细菌清除率90.00%均高于对照组的73.33%、66.67%(P<0.05)。治疗后,两组患者血清IL-6、IL-8水平低于治疗前,且实验组的IL-6(29.53±6.33)pg/ml、IL-8(3.38±0.69)pg/ml低于对照组的(34.09±9.84)、(4.01±0.85)pg/ml(P<0.05)。结论 对急性呼吸窘迫综合征患者合并铜绿假单胞菌呼吸道感染患者给予头孢他啶-阿维巴坦治疗,可促进患者体内细菌的清除,消除体内炎性因子,提升临床疗效,值得临床推广应用。

Objective To explore the effect of ceftazidime-avibactam(CAZ-AVI)in acute respiratory distress syndrome(ARDS)patients with Pseudomonas aeruginosa respiratory infection.Methods 60 patients with acute respiratory distress syndrome complicated with Pseudomonas aeruginosa respiratory tract infection were selected as research subjects,and were divided into a control group and an experimental group by random number table method,with 30 cases in each group.The control group received basic treatment,and the experimental group was treated with ceftazidime-avibactam on the basis of the control group.The clinical efficacy,bacterial clearance and serum levels of interleukin-6 and IL-8 before and after treatment were compared between the two groups.Results The experimental group had total effective rate of 93.33%and bacterial clearance rate of 90.00%,which were higher than 73.33%and 66.67%in the control group(P<0.05).After treatment,the serum IL-6 and IL-8 levels in both groups were lower than those before treatment;the experimental group had IL-6 of(29.53±6.33)pg/ml and IL-8 of(3.38±0.69)pg/ml,which were lower than(34.09±9.84)and(4.01±0.85)pg/ml in the control group(P<0.05).Conclusion In patients with acute respiratory distress syndrome complicated with Pseudomonas aeruginosa respiratory infection,the treatment of ceftazidime-avibactam can promote the elimination of bacteria and inflammatory factors in the patients,and promote the improvement of clinical efficacy,which is worthy of clinical application.